Pliant Therapeutics/PLRX

$17.21

5.96%
-
1D1W1MYTD1YMAX

About Pliant Therapeutics

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, bexotegrast (PLN-74809), is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. Its second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs targeting muscular dystrophies. It is also developing PLN-101095 an oral, dual inhibitor of αvß8 and αvß1 integrins for the treatment of solid tumors. Its clinical programs also include PLN-101325, an allosteric agonistic monoclonal antibody against α7β1 for treatment of muscular dystrophies.

Ticker

PLRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bernard Coulie

Employees

124

Headquarters

South san francisco, United States

PLRX Metrics

BasicAdvanced
$994.87M
Market cap
-
P/E ratio
-$2.78
EPS
1.16
Beta
-
Dividend rate

What the Analysts think about PLRX

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 13 analysts.
140.91% upside
High $53.00
Low $24.00
$17.21
Current price
$41.46
Average price target

PLRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-100%
Net income
$-41.4M
0.73%
Profit margin
0%
-100%

PLRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.68%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.72
-$0.67
-$0.70
-$0.70
-
Expected
-$0.70
-$0.67
-$0.71
-$0.78
-$0.81
Surprise
2.84%
0.25%
-1.87%
-9.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Pliant Therapeutics stock

Buy or sell Pliant Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing